Evidence map›Paper›PMID 36437688›Full record

Trial reportBritish journal of clinical pharmacology2023

The effect of TRV027 on coagulation in COVID-19: A pilot randomized, placebo-controlled trial.

Alexander J Robbins, Nur Amalina Che Bakri, Edward Toke-Bjolgerud, Aaron Edwards, Asha Vikraman, Cathy Michalsky, Michael Fossler, Nana-Marie Lemm, Savviz Medhipour, William Budd and 13 more

Registry-linked trialOpen access · hybridAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in British journal of clinical pharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04419610 (Investigating the Relationship Between the Renin Angiotensin System and the Coagulopathy Associated With COVID-19), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04419610 early_phase1completednot on this map

Investigating the Relationship Between the Renin Angiotensin System and the Coagulopathy Associated With COVID-19

TypeinterventionalSponsorImperial College LondonRan2020 to 2021Enrolled28ConditionsCOVIDArmsTRV027, sodium chloride 0.9%
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 6 institutions in 1 country.

Alexander J RobbinsImperial College Research Facility, Imperial College London, London, UK.ORCID 0000-0001-6929-5802
Nur Amalina Che BakriImperial College Healthcare NHS Trust, London, UK.
Edward Toke-BjolgerudImperial College Healthcare NHS Trust, London, UK.
Aaron EdwardsImperial College Research Facility, Imperial College London, London, UK.
Asha VikramanImperial College Research Facility, Imperial College London, London, UK.
Cathy MichalskyTrevena, Inc., Chesterbrook, Pennsylvania, USA.
Michael FosslerTrevena, Inc., Chesterbrook, Pennsylvania, USA.
Nana-Marie LemmImperial College Research Facility, Imperial College London, London, UK.
Savviz MedhipourImperial College Research Facility, Imperial College London, London, UK.
William BuddImperial College Research Facility, Imperial College London, London, UK.
Athanasia GravaniImperial College Research Facility, Imperial College London, London, UK.
Lisa HurleyImperial College Research Facility, Imperial College London, London, UK.
Vikas KapilWilliam Harvey Research Institute, Centre for Cardiovascular Medicine and Devices, Faculty of Medicine and Dentistry, Queen Mary University London, London, UK.
Aimee JacksonCancer Research Clinical Trials Unit, University of Birmingham, Birmingham, UK.
Dagan LonsdaleDepartment of Clinical Pharmacology, St George's University of London, London, UK.ORCID 0000-0003-0838-921X
Victoria LathamImperial College Healthcare NHS Trust, London, UK.
Michael LaffanCentre for Haematology, Imperial College London, London, UK.
Neil ChapmanImperial College Healthcare NHS Trust, London, UK.ORCID 0000-0003-1307-9275
Nichola CooperDepartment of Inflammation and Immunity, Imperial College London, London, UK.
Richard SzydloCentre for Haematology, Imperial College London, London, UK.
Joseph BoyleImperial College Healthcare NHS Trust, London, UK.
Katrina M PollockImperial College Research Facility, Imperial College London, London, UK.
David OwenImperial College Research Facility, Imperial College London, London, UK.
NIHR Imperial Biomedical Research Centre · GBImperial College Healthcare NHS Trust · GBImperial College London · GBCancer Research UK Clinical Trials Unit · GBQueen Mary University of London · GBSt George's, University of London · GB

Funding

British Heart Foundation RE/18/4/34215Cancer Research UK 25354Medical Research Council MR/N008219/1Medical Research Council MR/T031891/1Medical Research Council MR/W024977/1
6 · The paper itself

Abstract

COVID-19 causes significant thrombosis and coagulopathy, with elevated D-dimer a predictor of adverse outcome. The precise mechanism of this coagulopathy remains unclear; one hypothesis is that loss of angiotensin-converting enzyme 2 activity during viral endocytosis leads to pro-inflammatory angiotensin-II accumulation, loss of angiotensin-1-7 and subsequent vascular endothelial activation. We undertook a double-blind randomized, placebo-controlled experimental medicine study to assess the effect of TRV027, a synthetic angiotensin-1-7 analogue on D-dimer in 30 patients admitted to hospital with COVID-19. The study showed a similar rate of adverse events in TRV027 and control groups. There was a numerical decrease in D-dimer in the TRV027 group and increase in D-dimer in the placebo group; however, this did not reach statistical significance (P = .15). A Bayesian analysis demonstrated that there was a 92% probability that this change represented a true drug effect.

Indexed as

Blood Coagulation DisordersCOVID-19AngiotensinsBayes TheoremDouble-Blind MethodHumansOligopeptidesPilot ProjectsTreatment OutcomeAngiotensinsOligopeptidesSar-Arg-Val-Tyr-Ile-His-Pro-Ala-OHclinical trialscoagulationrandomized controlled trial

Identifiers

PMID36437688
PMCPMC10952550
OpenAlexW4310030295

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.